Long-Acting Antiretrovirals: Where Are We now?

Amesika N. Nyaku, Sean G. Kelly, Babafemi O. Taiwo

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations

Abstract

Purpose of Review: Current HIV treatment options require daily use of combination antiretroviral drugs. Many persons living with HIV experience treatment fatigue and suboptimal adherence as a result. Long-acting antiretroviral drugs are being developed to expand options for HIV treatment. Here, we review the agents in development, and evaluate data from recent clinical trials. In addition, we anticipate challenges to successful widespread use of long-acting antiretrovirals. Recent Findings: Parenteral nanosuspensions of cabotegravir and rilpivirine, and dapivirine vaginal ring are the farthest in clinical development. Long-acting modalities in earlier development stages employ drug-loaded implants, microparticles, or targeted mutagenesis, among other innovations. Summary: Long-acting antiretroviral drugs promise new options for HIV prevention and treatment, and ways to address poor adherence and treatment fatigue. Further studies will identify the long-acting agents or combinations that are suitable for routine use. Creative solutions will be needed for anticipated implementation challenges.

Original languageEnglish (US)
Pages (from-to)63-71
Number of pages9
JournalCurrent HIV/AIDS reports
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2017

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Keywords

  • HIV prevention
  • HIV treatment
  • Long-acting antiretrovirals
  • Pre-exposure prophylaxis

Fingerprint Dive into the research topics of 'Long-Acting Antiretrovirals: Where Are We now?'. Together they form a unique fingerprint.

Cite this